Inspire Medical’s Upper Airway Stimulator Impresses FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
FDA’s Anesthesiology and Respiratory Devices Panel endorsed Inspire Medical Systems’ PMA for the Inspire upper airway stimulation system at a Feb. 20 meeting. Inspire is intended for patients with sleep apnea who have not responded to continuous positive airway pressure therapy.
You may also be interested in...
News Briefs: Panel OKs Sleep Apnea Stimulator; Two Stryker Buys; TAVR Updates
FDA panel unanimously endorses Inspire upper airway stimulator. Stryker buys Berchtold and Pivot. First randomized U.S. study of embolic protection during transcatheter aortic valve replacement approved. More news.
‘Aspire To Abide By’ Advertising Laws Crucial For Direct Seller’s Defense Against FTC Complaint
In other finding at odds with previous court decisions, federal judge says direct seller Neora doesn’t have an “agency relationship” to its independent sales representatives and isn’t responsible for ad claims they post.
Direct Seller’s Data Counters FTC’s Pyramid Scheme Complaint Based On ‘Assumption’ About Sales
Ruling in Texas federal court on FTC complaint against Neora could serve as instructions for agency on how not to prosecute pyramid scheme allegations and for direct sellers about operating businesses so regulators find no hint of sales associates’ compensation plans based more on recruiting additional participants than on selling products.